Literature DB >> 15943770

Antimicrobial susceptibility variation of 50 anaerobic periopathogens in aggressive periodontitis: an interindividual variability study.

N Lakhssassi1, N Elhajoui, J-P Lodter, J-L Pineill, M Sixou.   

Abstract

BACKGROUND/AIMS: The frequent use of antibiotics in developed countries has led to the emergence of widespread bacterial resistance. In this study, the interindividual variability of the antibiotic susceptibility of 50 putative microorganisms in aggressive periodontitis patients has been evaluated by means of VC (variation coefficient).
MATERIAL AND METHODS: A total of 60 microbial samples were collected from 20 adult patients diagnosed with aggressive periodontitis (2-4 samples by patient). Bacterial strains of Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, Fusobacterium nucleatum, and Peptostreptococcus micros were isolated according to Slots' rapid identification method. The susceptibilities to 10 antibiotics were studied: penicillin G (PEN), ampicillin (AMP), amoxicillin (AMX), amoxicillin/clavulanate (AMC), tetracycline (TET), doxycycline (DOX), ciprofloxacin (CIP), erythromycin (ERY), spiramycin (SPI) and clindamycin (CLIN), using the Disk Diffusion Susceptibility test (DDS test: Kirby-Bauer's modified method for anaerobic bacteria). The broth microdilution Minimum Inhibitory Concentration test was carried out as a control test.
RESULTS: Among the 50 identified bacteria, 15 were P. gingivalis, 12 P. intermedia, 8 T. forsythia, 9 F. nucleatum, and 6 P. micros. The results of the DDS test show that penicillins (especially AMC, AMP, and AMX), cyclines (especially DOX) and CLIN are highly effective against the 50 anaerobic studied bacteria. CIP and ERY have the lowest efficacy against those bacteria. CIP shows a very variable activity according to anaerobic bacteria species, being particularly inactive against P. gingivalis and very efficient against T. forsythia and P. micros. SPI is also highly efficient but not against P. micros.
CONCLUSIONS: The interindividual susceptibility of principal periodontal pathogens to antibiotics is not homogeneous and seems to vary according to bacterial species and antimicrobial molecules. This variability seems to be greater with older molecules (PEN, TET, ERY) than with more recent ones, which indicates more stable results (AMC, AMX, AMP, and DOX). P. intermedia appeared to be the bacteria most resistant to penicillins and showed the highest coefficient variation. Together with scaling and root planing, the combination of two antibiotics would therefore seem to be recommended in the treatment of aggressive periodontitis, particularly in the presence of P. intermedia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943770     DOI: 10.1111/j.1399-302X.2005.00225.x

Source DB:  PubMed          Journal:  Oral Microbiol Immunol        ISSN: 0902-0055


  16 in total

1.  Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.

Authors:  Yangsoon Lee; Yongjung Park; Myung Sook Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 2.  Microbiology and treatment of acute apical abscesses.

Authors:  José F Siqueira; Isabela N Rôças
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Gender-associated differences in oral microbiota and salivary biochemical parameters in response to feeding.

Authors:  M Minty; P Loubières; T Canceill; V Azalbert; R Burcelin; F Tercé; V Blasco-Baque
Journal:  J Physiol Biochem       Date:  2020-07-09       Impact factor: 4.158

4.  Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.

Authors:  F D Wang; C H Liao; Y T Lin; W H Sheng; P R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-15       Impact factor: 3.267

5.  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

6.  Comparative antimicrobial efficacy of herbal alternatives (Emblica officinalis, Psidium guajava), MTAD, and 2.5% sodium hypochlorite against Enterococcus faecalis: An in vitro study.

Authors:  Sandeep Dubey
Journal:  J Oral Biol Craniofac Res       Date:  2016-01-20

7.  Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis.

Authors:  Laura J Sherrard; Kathryn A Graham; Stef J McGrath; Leanne McIlreavey; Joseph Hatch; Marianne S Muhlebach; Matthew C Wolfgang; Deirdre F Gilpin; J Stuart Elborn; Thamarai Schneiders; Michael M Tunney
Journal:  J Antimicrob Chemother       Date:  2013-05-21       Impact factor: 5.790

8.  Fungi treated with small chemicals exhibit increased antimicrobial activity against facultative bacterial and yeast pathogens.

Authors:  Christoph Zutz; Dragana Bandian; Bernhard Neumayer; Franz Speringer; Markus Gorfer; Martin Wagner; Joseph Strauss; Kathrin Rychli
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

9.  High-fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogens.

Authors:  Vincent Blasco-Baque; Matteo Serino; Jean-Noël Vergnes; Elodie Riant; Pascale Loubieres; Jean-François Arnal; Pierre Gourdy; Michel Sixou; Rémy Burcelin; Philippe Kemoun
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

Review 10.  Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences.

Authors:  Matteo Serino; Vincent Blasco-Baque; Simon Nicolas; Remy Burcelin
Journal:  Curr Cardiol Rep       Date:  2014-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.